Investigating a new target for diagnosing and treating prostate cancer
PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-10877944
This study is looking at how a specific protein called PSMA affects prostate cancer, especially when it becomes harder to treat after hormone therapy, and aims to create new personalized treatments and better ways to diagnose and track the disease for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10877944 on ClinicalTrials.gov |
What this research studies
This research focuses on prostate cancer, particularly the challenges faced when patients progress to castration-resistant prostate cancer (CRPC) after initial hormone therapy. The team aims to explore the role of prostate-specific membrane antigen (PSMA) in cancer growth, utilizing its enzymatic activity to develop a novel personalized therapy. By understanding how PSMA interacts with key signaling pathways, the researchers hope to create new treatment strategies that could improve patient outcomes. Additionally, they are developing a companion imaging assay to help diagnose and monitor prostate cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, particularly those who have progressed to castration-resistant prostate cancer.
Not a fit: Patients with early-stage prostate cancer who have not yet undergone hormone therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRIMM, JAN — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: GRIMM, JAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.